About two thirds of breast cancers are classified as “hormone receptor positive” disease. These cancer cells express a group of proteins that bind to hormones, including estrogen and progesterone, ...

Vepdegestrant becomes the first FDA-approved heterobifunctional protein degrader (PROTAC) in breast cancer, targeting ER ...

A novel artificial intelligence (AI) application capable of diagnosing endocrine cancers with speed and accuracy is being presented Sunday at ENDO 2025, the Endocrine Society's annual meeting in San ...

VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...

The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially ...

Preclinical studies by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, showed how a new combination therapy for hormone-resistant, ...

Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...

Beyond weight loss, GLP-1s may offer a "two-for-one" benefit by protecting heart health, which is the leading cause of ...

More than 46% of women with stage 1 or 2 breast cancer chose to continue endocrine therapy after five years, a recent study found. The study, published in the Journal of the National Cancer Institute, ...

Some cancer treatments can affect the body’s endocrine system, prompting CU Anschutz physicians to establish an endocrine-oncology clinic that helps patients get specialized care quickly University of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Most women with breast cancer who paused endocrine ...